Cellivery Therapeutics, Inc. is a Korea-based company principally engaged in the research and development of medicines and biotherapeutics. The Company develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The Company research and develop therapeutic drug candidates such as Parkinsonâs disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-05-18 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement and Estimates

income-statement-evolution-chart CELLIVERY-THERAPEUTICS-IN

More financial data

End-of-day quote Korea S.E. Other stock markets 2023-03-23			5-day change	1st Jan Change
6,680.00 ^KRW	-29.91%		-.--%	-.--%

Apr. 05	Cellivery Therapeutics, Inc.(KOSDAQ:A268600) dropped from S&P Global BMI Index	CI
Nov. 17	Cellivery Therapeutics, Inc. acquired Ajin Clean Co., Ltd. from SVAJ Holdings for KRW 14.2 billion.	CI

Capitalization	248B 169M 166M 156M 139M 244M 14.69B 275M 1.91B 709M 6.01B 636M 622M 26.71B	P/E ratio 2022	-4.02x	P/E ratio 2023	-7.51x
Enterprise value	293B 200M 196M 184M 164M 288M 17.33B 325M 2.26B 837M 7.1B 751M 734M 31.52B	EV / Sales 2022	20.8x	EV / Sales 2023	15.4x
Free-Float	86.19%	Yield 2022 *	-	Yield 2023	-

Cellivery Therapeutics, Inc.(KOSDAQ:A268600) dropped from S&P Global BMI Index	23-04-05	CI
Cellivery Therapeutics, Inc. acquired Ajin Clean Co., Ltd. from SVAJ Holdings for KRW 14.2 billion.	21-11-16	CI
Cellivery Therapeutics, Inc. agree to acquire Ajin Clean Co., Ltd. for KRW 14.9 billion.	21-11-15	CI
Cellivery Therapeutics, Inc. announced that it has received KRW 38.9997004 billion in funding	21-10-14	CI
Cellivery Therapeutics to Raise Nearly $17 Million Through Stock Sale	21-09-30	MT
Cellivery Therapeutics, Inc. announced that it expects to receive KRW 38.9997004 billion in funding	21-09-29	CI
Cellivery Therapeutics to Raise $13 Million from Stock Offering	21-09-23	MT
Cellivery Therapeutics, Inc. announced that it has received KRW 43.9988081 billion in funding from a group of investors	20-08-18	CI
Cellivery Therapeutics, Inc. announced that it expects to receive KRW 43.9988081 billion in funding from a group of investors	20-08-05	CI
Cellivery Therapeutics, Inc.(KOSDAQ:A268600) added to S&P Global BMI Index	19-03-18	CI
Cellivery Therapeutics, Inc has completed an IPO in the amount of KRW 28.5 billion.	18-11-08	CI
Cellivery Therapeutics, Inc has filed an IPO.	18-07-11	CI

Director	Title	Age	Since
Dae-Woong Cho CEO	Chief Executive Officer	56	2014-08-27
Sun-Hong Kwon PRN	Corporate Officer/Principal	51	2021-03-28
Byung-Hwa Lee AUD	Comptroller/Controller/Auditor	61	2019-03-21

Cellivery Therapeutics, Inc. Stock

Equities

A268600

KR7268600004

Biotechnology & Medical Research

Valuation: Cellivery Therapeutics, Inc.

Latest news: Cellivery Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cellivery Therapeutics, Inc.

ETFs: Cellivery Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
Dae-Woong Cho BRD	Director/Board Member	56	2014-08-27
Sun-Hong Kwon BRD	Director/Board Member	51	2021-03-28

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
CELLIVERY THERAPEUTICS, INC.	-29.91%	-.--%	-.--%	-64.37%	169M
VERTEX PHARMACEUTICALS INCORPORATED	+0.93%	+2.70%	-4.62%	+82.44%	106B
REGENERON PHARMACEUTICALS, INC.	+2.87%	+0.09%	-23.18%	+16.36%	77.13B
ARGENX SE	+0.12%	+2.96%	+86.09%	+159.56%	39.83B
BIONTECH SE	-7.42%	-5.38%	+9.82%	-43.97%	27.27B
WUXI APPTEC CO., LTD.	-0.36%	+0.51%	-25.97%	-54.10%	20.72B
BEIGENE, LTD.	+4.47%	+2.20%	+5.36%	-21.84%	19.67B
NEUROCRINE BIOSCIENCES, INC.	+1.51%	+4.52%	+8.33%	+80.55%	14.48B
GENMAB A/S	+2.43%	+0.53%	-22.84%	-30.15%	13.58B
SUMMIT THERAPEUTICS INC.	+1.82%	+4.04%	+486.29%	+670.13%	13.4B
Average	-2.35%	-2.75%	+51.93%	+79.46%	33.27B
Weighted average by Cap.	+0.83%	+1.01%	+21.98%	+70.24%

	2022	2023
Net sales	23.16B 15.79M 15.48M 14.52M 12.99M 22.76M 1.37B 25.67M 178M 66.09M 561M 59.29M 58.02M 2.49B	18.86B 12.86M 12.61M 11.83M 10.58M 18.54M 1.12B 20.91M 145M 53.83M 457M 48.3M 47.25M 2.03B
Net income	-75.16B -51.26M -50.25M -47.12M -42.16M -73.88M -4.44B -83.31M -578M -214M -1.82B -192M -188M -8.08B	-32.57B -22.21M -21.78M -20.42M -18.27M -32.02M -1.93B -36.1M -251M -92.95M -788M -83.39M -81.59M -3.5B
Net Debt	48.13B 32.83M 32.18M 30.17M 27M 47.31M 2.85B 53.35M 370M 137M 1.17B 123M 121M 5.18B	44.76B 30.53M 29.93M 28.06M 25.11M 44M 2.65B 49.61M 344M 128M 1.08B 115M 112M 4.81B